SVNT...........IMHO is ONXX at $13/sh..............In other words, I am predicting an approximate 10-fold move in SVNT's mkt cap from current levels, and here's how we get there: First, SVNT's lead orphan rare, disease drug Krystexxa is grossly mispriced. Right now it is priced at only $5,390/dose vs $34,000/dose for Acthar. SVNT is now gradually raising Krystexxa's price to align it with the rare disease tophi market. Once SVNT raises Krystexxa's price to just $10,000/dose before YE, SVNT will be profitable next yr and trade for 4-5x sales. Once Krystexxa's price goes to only $10,000/dose SVNT will generate sufficient revs next yr(my est is around $125 mil) to turn a profit. SVNT's breakeven is around $95 mil. Once profitable, SVNT will trade for at least 4-5x sales and have a market cap between $400-$500 mil. That's a 10-fold move from current levels. Best wishes to all.